# US Patent 7,214,506: Efinaconazole Onychomycosis Claims, Scope, Expiration, and Patent Landscape

US Patent 7,214,506 is a method-of-use patent covering topical treatment of onychomycosis with a broad genus of triazole antifungal compounds. Claim 2 narrows the protection to efinaconazole, the active ingredient in Jublia 10% topical solution. The patent does not claim a particular formulation, concentration, applicator, dosing schedule, or manufacturing process. Its commercial significance is therefore concentrated in the use of efinaconazole for nail fungus.

The patent was assigned to Kaken Pharmaceutical Co., Ltd. and became central to the US exclusivity position for Jublia, which was approved by the FDA in 2014. The patent’s base 20-year term ran from the US filing date and reached expiration in 2022, subject to any patent-term adjustment reflected in the official patent record. Later Jublia formulation patents, rather than US 7,214,506 alone, became the more relevant barriers to generic entry.

What does US Patent 7,214,506 protect?

US 7,214,506 protects a treatment method with four central elements:

A subject has onychomycosis.
An antifungal compound within the claimed chemical formula is used.
The compound is administered topically.
The compound is administered to a nail in a therapeutically effective amount.

Claim 1 is a genus claim. It covers compounds having a substituted or unsubstituted phenyl group, a triazole or related heterocyclic structure, defined substituents on R1 and R2, and specified stereochemical centers. The claim permits substantial variation in the chemical substituents.

Claim 2 is materially narrower. It identifies:

(2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylenepiperidin-1-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol

That compound is efinaconazole.

What is the protected subject matter?

Claim feature	Scope
Disease	Onychomycosis
Administration route	Topical
Site of administration	A nail
Active agent	Broad formula in claim 1; efinaconazole in claim 2
Dose	Any therapeutically effective amount
Concentration	Not specified
Vehicle	Not specified
Treatment schedule	Not specified
Nail type	Not limited to toenails or fingernails
Pathogen	Not limited to a specific fungal species

The absence of concentration and vehicle limitations gives the method claims potentially broad reach against topical efinaconazole products. A product containing efinaconazole could fall within claim 2 if it is promoted or used for topical treatment of onychomycosis, regardless of whether it uses the same vehicle or applicator as Jublia.

How broad is claim 1 compared with claim 2?

Claim 1 covers a chemical genus. Claim 2 covers one specific stereochemically defined compound.

The breadth difference is commercially important:

A competitor using efinaconazole would face claim 2 directly, assuming the method-of-use limitations are practiced.
A competitor using a different compound within the claim 1 formula could face claim 1 even if the compound were not efinaconazole.
A compound outside the claim 1 formula would not literally infringe the chemical limitation, although the doctrine of equivalents could become relevant.
Claim 1 does not require the specific 2R,3R configuration recited in claim 2, subject to the patent’s formal claim construction and specification.

Claim 1 limitations that may affect enforcement

The key litigation issues would likely include:

whether the accused condition is legally “onychomycosis”;
whether administration is directed to the nail rather than merely surrounding skin;
whether the amount is therapeutically effective;
whether the accused compound falls within the formula;
whether the claim adequately describes and enables the full chemical genus;
whether the stereochemical language covers the accused stereoisomer or mixture.

Because the chemical formula was omitted from the supplied text, the exact scope of the ring system and substituent attachment points must be read from the issued patent drawings and specification. The quoted claim language alone does not permit a complete Markush-structure infringement map.

What drug is covered by claim 2?

Claim 2 covers efinaconazole, marketed in the United States as Jublia.

Item	Data
Active ingredient	Efinaconazole
Brand	Jublia
Dosage form	Topical solution
Commercial strength	10%
US sponsor at approval	Dow Pharmaceutical Sciences, a Valeant company
Current commercial group	Bausch Health / Bausch + Lomb interests
FDA indication	Topical treatment of toenail onychomycosis
Original FDA approval	2014
FDA application	NDA 203567

The FDA approved Jublia for treatment of toenail onychomycosis caused by susceptible organisms. The product is applied directly to the affected toenails and adjacent skin, generally once daily for the labeled treatment period. The approved label is narrower than the patent in some respects because the label focuses on toenails, while claim 2 is not expressly limited to toenails. (FDA, 2014)

When did US Patent 7,214,506 lose exclusivity?

The ordinary 20-year patent term was calculated from the US nonprovisional filing date, producing a base expiration in 2022. Any patent-term adjustment could extend the enforceable term beyond the base date. The controlling date is the expiration date printed in the USPTO patent record and reflected, where applicable, in FDA Orange Book records.

The patent’s commercial exclusivity should be separated into three periods:

Exclusivity component	Effect
US Patent 7,214,506	Method-of-use protection for the claimed antifungal treatment
FDA new chemical entity exclusivity	Five-year regulatory exclusivity associated with efinaconazole, subject to the applicable statutory framework
Later formulation patents	Potentially extended protection for the Jublia formulation and delivery system

The expiration of US 7,214,506 did not automatically eliminate every barrier to an efinaconazole generic. A generic applicant still had to address any unexpired formulation, composition, delivery, or method-of-use patents listed for Jublia.

What is the Orange Book status of US Patent 7,214,506?

US 7,214,506 was listed in connection with Jublia as a method-of-use patent. An Orange Book listing does not establish validity. It identifies patent information submitted by the NDA holder for FDA-approved products.

For an ANDA applicant, the patent could trigger:

a Paragraph IV certification alleging that the patent is invalid, unenforceable, or not infringed;
a 30-month stay if the NDA holder timely filed patent litigation;
a section viii statement or label carve-out if the patented use could be omitted from the proposed generic label;
potential launch restrictions based on other listed Jublia patents.

A method-of-use patent can be less restrictive than a formulation patent when a generic applicant can obtain approval with a legally permissible label that omits the patented indication. That strategy is more difficult where the only commercially viable use of the active ingredient is the patented use or where promotional conduct creates induced-infringement exposure.

What later patents protect Jublia formulations?

Jublia’s broader commercial patent estate includes later patents directed to topical formulations and related product characteristics. Public FDA and product-label materials identify multiple Jublia patent numbers, including US 8,367,649 and later continuation or related patents. The exact enforceability of each patent depends on claim scope, terminal disclaimers, patent-term adjustment, Orange Book listing, and litigation outcomes.

Formulation protection compared with US 7,214,506

Protection type	US 7,214,506	Later Jublia patents
Primary subject	Treatment method	Formulation, composition, or product characteristics
Efinaconazole specifically claimed	Yes, in claim 2	Often, depending on the claim
Requires onychomycosis treatment	Yes	Not necessarily
Requires topical nail administration	Yes	Not necessarily
Protects vehicle or excipients	No express limitation in quoted claims	Potentially
Relevance to ANDA label carve-out	High	Often higher for product-specific approval
Typical design-around route	Use different active compound or avoid claimed use	Change vehicle, excipients, concentration, or manufacturing conditions

A generic applicant could challenge the method patent while separately addressing formulation patents. A Paragraph IV challenge to US 7,214,506 would not, by itself, clear the entire Jublia patent estate.

Which companies have challenged Jublia patent protection?

Publicly reported Jublia patent litigation has involved generic-drug companies, including Taro Pharmaceuticals, in connection with ANDA filings for efinaconazole topical products. Bausch-affiliated entities have brought patent actions under the Hatch-Waxman framework to protect listed Jublia patents.

The principal litigation questions in such cases generally include:

whether the generic product practices the patented method;
whether the proposed label induces use for onychomycosis;
whether formulation patents are infringed;
whether the patents are invalid for obviousness, anticipation, lack of written description, or lack of enablement;
whether a proposed label carve-out removes the patented use.

A complete current litigation disposition requires review of the relevant district court docket, Federal Circuit decisions, settlement filings, and FDA approval records. The claim text alone does not establish whether a particular defendant has settled, prevailed, or launched.

What Paragraph IV risks exist for an efinaconazole generic?

An efinaconazole ANDA applicant would typically evaluate four routes.

Paragraph IV challenge

The applicant could allege that the listed method or formulation patents are invalid or not infringed. The strongest invalidity arguments would likely focus on:

obviousness based on earlier triazole antifungal compounds;
inadequate written description for the broad genus claim;
lack of enablement across the full Markush scope;
anticipation if prior art disclosed the claimed compound and nail-fungus use;
indefiniteness arising from the chemical formula or stereochemical definitions.

Claim 2 is more vulnerable to prior-art comparison focused specifically on efinaconazole. Claim 1 presents a broader written-description and enablement profile because it reaches numerous substituent combinations.

Section viii carve-out

The applicant could seek approval with a label omitting the patented indication or narrowing the approved use. This approach is difficult if the product’s proposed labeling, prescribing pattern, or promotional materials would still encourage treatment of onychomycosis.

Launch after patent expiration

Once all relevant listed patents expire or are removed, an approved ANDA could launch without prevailing in a Paragraph IV case. Patent expiration must be assessed patent by patent.

Settlement-based entry

A settlement could establish a negotiated generic launch date, licensing terms, or restrictions. The commercial entry date may differ from the expiration date of US 7,214,506.

How strong is the patent estate for efinaconazole?

US 7,214,506 is strongest against a product that uses efinaconazole to treat onychomycosis during the enforceable patent term. Its strengths are:

claim 2 identifies the commercial active ingredient;
the treatment method corresponds closely to the approved use;
the claim does not require a narrow concentration or vehicle;
induced-infringement theories may apply where a generic label directs nail-fungus treatment.

Its limitations are:

it is a method claim, not a standalone composition claim;
sale of efinaconazole without practicing or inducing the claimed method may not create direct infringement;
claim 1 may face written-description, enablement, and obviousness challenges;
expiration of the patent removes the principal legal barrier created by this patent;
later formulation patents may be more important to product-level exclusivity.

The estate is therefore more defensible as a coordinated portfolio than as a single-patent barrier. The commercial risk for a generic depends on the surviving formulation patents, the final ANDA label, and any litigation settlement.

Does efinaconazole have biosimilar risk?

No. Efinaconazole is a small-molecule antifungal, not a biologic. Biosimilar provisions under the Public Health Service Act do not apply. Competitive entry would proceed through the ANDA pathway for a generic drug, not through a biosimilar application.

How does efinaconazole compare with competing onychomycosis drugs?

Product	Active ingredient	Route	Patent risk profile
Jublia	Efinaconazole	Topical	Method and formulation patents
Kerydin	Tavaborole	Topical	Separate small-molecule and formulation estate
Penlac	Ciclopirox	Topical	Older product with substantially earlier patent history
Oral terbinafine	Terbinafine	Oral	Different safety, labeling, and patent profile
Oral itraconazole	Itraconazole	Oral	Different systemic exposure and method claims

Efinaconazole competes primarily with tavaborole and oral terbinafine. Its patent landscape is distinct because the commercial product depends on a topical solution designed to penetrate the nail without debridement or removal of the nail plate. Formulation and delivery claims can therefore have greater commercial value than the expired or expiring use claim alone.

What manufacturing and geographic barriers remain?

US 7,214,506 does not claim a manufacturing process in the quoted claims. It therefore does not create a direct manufacturing barrier. Manufacturing risk may arise from later patents covering:

solvent systems;
solubilization of efinaconazole;
impurity control;
crystallization or solid-state forms;
filling and packaging;
applicator configuration;
stability characteristics.

Geographic protection is territorial. A US patent cannot block manufacture, sale, or use outside the United States unless corresponding foreign patents exist. Kaken and its licensees may hold related patent families in Japan, Europe, Canada, and other markets, but each jurisdiction requires separate validity and expiration analysis.

Key Takeaways

US 7,214,506 is a method-of-use patent for topical treatment of onychomycosis.
Claim 1 covers a broad genus of triazole antifungal compounds.
Claim 2 specifically covers efinaconazole, the active ingredient in Jublia.
The patent does not expressly claim Jublia’s 10% concentration, vehicle, applicator, or dosing schedule.
The base US patent term reached expiration in 2022, subject to any patent-term adjustment.
Later Jublia formulation patents became more important to generic-entry analysis.
Efinaconazole faces generic, not biosimilar, competition.
A Paragraph IV challenge could target validity or infringement, while a section viii strategy could seek a label carve-out.
The strongest remaining barriers are product-specific formulation and delivery patents, not the quoted method claim alone.
A complete launch assessment requires review of all Orange Book-listed patents and the final ANDA label.

FAQs About US Patent 7,214,506 and Efinaconazole

Is US 7,214,506 a composition-of-matter patent?

No. The quoted claims are method claims. Claim 2 identifies efinaconazole as the compound used in the method, but the claim requires topical administration to a nail of a subject with onychomycosis.

Does US 7,214,506 cover all efinaconazole products?

No. It covers practicing the claimed treatment method. Product-level protection may arise from separate composition or formulation patents.

Can a generic efinaconazole product avoid US 7,214,506?

Potentially. A generic applicant could pursue a Paragraph IV certification, a permissible label carve-out, or launch after expiration. The result depends on the approved label and remaining patents.

Is claim 1 vulnerable because it covers many compounds?

Potentially. Broad genus claims can face written-description, enablement, obviousness, and indefiniteness challenges. The outcome depends on the patent specification, prosecution history, and prior art.

Does expiration of US 7,214,506 permit immediate Jublia generic launch?

Not necessarily. Other Orange Book-listed patents, regulatory requirements, litigation settlements, and ANDA approval timing may delay or restrict launch.

References

Food and Drug Administration. (2014). Jublia (efinaconazole) topical solution, 10%: Prescribing information. U.S. Department of Health and Human Services.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
United States Patent and Trademark Office. (2007). US Patent No. 7,214,506, antifungal agent. U.S. Department of Commerce.
Kaken Pharmaceutical Co., Ltd. (n.d.). Efinaconazole and related patent disclosures. Corporate and patent records.
Bausch Health Companies Inc. (2023). Annual report and product information for Jublia. Bausch Health Companies Inc.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bausch	JUBLIA	efinaconazole	SOLUTION;TOPICAL	203567-001	Jun 6, 2014	AB	RX	Yes	Yes	7,214,506	⤷ Start Trial				ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Japan	11/214369	Jul 28, 1999

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	434667	⤷ Start Trial
Australia	5852400	⤷ Start Trial
Canada	2391274	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,214,506

Which drugs does patent 7,214,506 protect, and when does it expire?

Summary for Patent: 7,214,506